| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Feb, 2028
(4 years from now) | |
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(5 months ago) | |
Reyvow is owned by Eli Lilly And Co.
Reyvow contains Lasmiditan Succinate.
Reyvow has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Reyvow are:
- US8748459
Reyvow was authorised for market use on 31 January, 2020.
Reyvow is available in tablet;oral dosage forms.
Reyvow can be used as acute treatment of migraine.
Drug patent challenges can be filed against Reyvow from 2024-02-01.
The generics of Reyvow are possible to be released after 05 December, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 2024-02-01
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
REYVOW family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic